The invention here relates to a product comprised of a cell line or lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in mammals and humans. All of the studies of cell-based cancer vaccines to date have one feature in common, namely the intention to use...
A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer. Roy S. Herbst, MD, PhD A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC). The ...
During the past 15 years, breakthrough discoveries have revolutionized the treatment landscape for most patients with lung cancer, progress that has helped fuel an overall drop in cancer mortality.1,2 However, options remain limited for the subgroup of patients with small cell lung cancer (SCLC)....
Here, we have summarised the intratumoural microbiota in a few cancers to understand their role in cancer progression (Table 1). Table 1 Characterization of the intratumoural microbiota in various cancers Full size table Lung cancer As the mucosa is in primary contact with the external ...
Gazyva: New Drug Gets Breakthrough Status Current Researchdoi:10.13140/RG.2.2.19871.28325Ayush SuriMehak BhansMansi PatelMcmaster Rare Disease Review
celebrate 10 years since cancer immunotherapy was recognized as the “breakthrough of the year”by Science magazinein 2013. Over 30 cancers are treatable with immunotherapy and thegoal of the awareness monthis to increase this number further and bring life-saving therapies to even more cancer ...
The success of the agency’s Oncology Center ofExcellence (OCE) to shepherd promising, though risky, cancer treatments through product development, testing and approval has spurred interest among a range of patient disease groups to gain similar priority treatment for new therapies for rare diseases ...
S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014). CAS PubMed PubMed Central Google Scholar Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372,...
Indeed, treatment approaches designed on the basis of an improved understanding of cancer biology have led to unprecedented responses in early phase trials, sometimes resulting in drug approvals in the absence of large-scale trials. At the same time, improved molecular diagnostic technologies have ...
(FDA) seeking approval of sunvozertinib for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutat...